Communiqués Formycon AG

Actions

FYB

DE000A1EWVY8

Recherche biotechnologique et médicale

Marché Fermé - Xetra 17:35:38 17/09/2026			Après clôture 20:36:16
19,80 ^EUR	-0,20%		19,77	-0,15%

26/08	Formycon AG : Berenberg reste à l'achat	ZD
12/08	Transcript : Formycon AG, H1 2026 Earnings Call, Aug 12, 2026

Communiqués

12/08	Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year	EQ
05/08	Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences	EQ
27/07	Formycon And OneSource Specialty Pharma Partner To Manufacture Biosimilars	AQ
14/07	Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars	EQ
10/06	Formycon AG Reports Results of Annual General Meeting 2026	EQ
28/05	Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026	EQ
22/05	Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
21/05	Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences	EQ
19/05	Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union	EQ
22/04	Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships	EQ
20/04	Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026	EQ
15/04	Formycon : announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements	PU
15/04	Formycon AG:	EQ
06/04	Formycon And Regeneron Settle European Aflibercept Biosimilar Litigation	AQ
19/03	Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer	EQ
18/03	Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025	EQ
04/03	Formycon AG publishes preliminary figures for the 2025 fiscal year	EQ
26/02	Formycon And Lotus Expand Collaboration In Asia-Pacific Region To Pembrolizumab Biosimilar	AQ
25/02	Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)	EQ
11/02	Formycon : Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region	PU
11/02	Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region	EQ
14/01	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
13/01	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
13/01	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
23/12	FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner	EQ